CheckMate 77T

Prespecified interim analysis results from CheckMate 77T trial of neoadjuvant nivolumab or placebo plus chemotherapy and adjuvant nivolumab or placebo in stage II to IIIB NSCLC, as presented at ESMO Congress 2023 and reported by Clinical Care Options (CCO)

CheckMate 77T: Perioperative Immunotherapy in Resectable NSCLC

肺癌围术期研究CheckMate-77T报捷，欧狄沃用于可切除肺癌再证疗效医药

Adding Adjuvant Nivolumab Builds on Standard of Care for

The Cancer News - Authoritative Resource for Everything About

CheckMate-77T Trial Meets Primary EFS End Point in Resectable NSCLC

Dr Amol Akhade on X: Checkmate 77T . Neoadjuvant nivo plus chemo

JCM, Free Full-Text

Neoadjuvant immunotherapy/target therapy trials.

Dr Amol Akhade on X: Perioperative Nivo . Checkmate 77T . HR of

News from ESMO - Lung Cancer Research Foundation

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Perioperative chemoimmunotherapy treatment in early stage NSCLC